You are here

Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
SKiN Centre for Dermatology
Peterborough, Ontario, K9J 1Z2 Canada
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Atopic Dermatitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-60 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at
least 6 months prior to Day 1 that has been clinically stable for at least 1 month
prior to Day 1 and is confirmed to be atopic dermatitis according to the criteria of
Hanifin and Rajka.

- Have a PGA score of 2 (mild) or 3 (moderate) at Day 1.

- Have atopic dermatitis on the head (including face, but excluding hair bearing scalp),
neck, trunk (excluding groin and genitals), or limbs including palms and soles
covering at least 2% of total body surface area (BSA) and up to and including 20% of
total BSA at Day 1. At least 2% of the total BSA will need to be on the head
(including face, but excluding hair bearing scalp), neck, trunk (excluding groin and
genitals), or limbs (excluding palms and soles).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence of certain skin conditions/infections at baseline

- Currently have atopic dermatitis on groin, genitals, palm or soles

- Have certain laboratory abnormalities at baseline

- Females who are pregnant, breastfeeding, or are of childbearing potential not using
highly effective contraception

NCT02001181
Pfizer
Completed
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Atopic Dermatitis
NCT02780167
All Genders
18+
Years
Multiple Sites
Allergic Contact Dermatitis
NCT00141180
All Genders
18+
Years
Multiple Sites
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
A Phase 2a, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis
The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Dermatitis, Atopic
  • Drug: Tofacitinib ointment 20mg/g
    Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
  • Drug: Placebo ointment (Vehicle)
    Placebo ointment (vehicle) twice daily (BID) for 4 weeks
  • Experimental: Treatment group A
    Intervention: Drug: Tofacitinib ointment 20mg/g
  • Placebo Comparator: Treatment B
    Intervention: Drug: Placebo ointment (Vehicle)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
69
September 2014
September 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at least 6 months prior to Day 1 that has been clinically stable for at least 1 month prior to Day 1 and is confirmed to be atopic dermatitis according to the criteria of Hanifin and Rajka.
  • Have a PGA score of 2 (mild) or 3 (moderate) at Day 1.
  • Have atopic dermatitis on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs including palms and soles covering at least 2% of total body surface area (BSA) and up to and including 20% of total BSA at Day 1. At least 2% of the total BSA will need to be on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs (excluding palms and soles).

Exclusion Criteria:

  • Evidence of certain skin conditions/infections at baseline
  • Currently have atopic dermatitis on groin, genitals, palm or soles
  • Have certain laboratory abnormalities at baseline
  • Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT02001181
A3921214
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now